Trouble sleeping is common in other neurodegenerative diseases, but past research has only suggested that it occurs in ...

Roy Woodlief, center, poses with Wake County Sheriff Donnie Harrison and Terry Putnam after Woodlief graduated the academy ...

Salt Lake City-based pharmaceutical company Clene Inc. has amended its grant subaward with Columbia University, securing up ...

Competing in a marathon could be considered quite the task for some, but not for one Amyotrophic Lateral Sclerosis (ALS) ...

Zydus’ Usnoflast receives US FDA orphan drug designation to treat amyotrophic lateral sclerosis: Our Bureau, Mumbai Thursday, January 23, 2025, 12:15 Hrs [IST] Zydus, a leading, ...

Zydus Lifesciences added 1.10% to Rs 987.60 after the company said that the USFDA had granted orphan drug designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic ...

targeting calpain-2 for people living with amyotrophic lateral sclerosis (ALS). With the clinical hold lifted, Amylyx is now working to open U.S. sites for screening, enrollment, and dosing.

Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for ...

About ProMIS Neurosciences Inc. ProMIS Neurosciences Inc. is a clinical stage biotechnology company focused on generating and ...

MAID is currently legal in 10 states and Washington, D.C., but eight other states are considering similar laws this year.

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...